Drug intelligence / Profile preview

HER2 CAR-NK

Development stage: Preclinical
Lead developer: TC BioPharm
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intracranial Injection, Intravenous Infusion

Overview

HER2 CAR-NK is an allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapeutic candidate designed to target solid tumors that express Human Epidermal Growth Factor Receptor 2 (HER2). It is currently in preclinical/early-stage development. TC BioPharm acquired the proprietary manufacturing processes and the therapeutic candidate in April 2024. This CAR-NK therapy is intended for use as a monotherapy or in combination with TC BioPharm's lead product, TCB-008, and aims to expand the company's pipeline into solid tumors and autoimmune diseases.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on HER2 CAR-NK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HER2 CAR-NK.

Explore the full profile